KC Has Scheduled a Live Webcast on The US Supreme Court Decision on FTC v. Actavis, Inc.

The Knowledge Group has scheduled a live webcast entitled: The US Supreme Court Decision on FTC v. Actavis, Inc.: The Legality of Reverse-Payment Settlements of Pharmaceutical Patent Infringement Litigations
By: The Knowledge Group, LLC
 
NEW YORK - July 17, 2013 - PRLog -- The Knowledge Group/The Knowledge Congress Live Webcast Series, brings together the world's leading authorities and industry participants through informative two -hour webcasts. It has scheduled a live webcast entitled: “The US Supreme Court Decision on FTC v. Actavis, Inc.: The Legality of Reverse-Payment Settlements of Pharmaceutical Patent Infringement Litigations and Its Implications for Firms, Individuals, and Innovation LIVE Webcast.” This two-hour event is scheduled on July 31, 2013 from 12:00 PM to 2:00 PM ET.

Event Synopsis:


"Reverse-payment" license agreements in settlement of Hatch-Waxman Act ANDA Paragraph IV patent infringement litigations are characterized by the transfer of valuable consideration to "generic" drug company defendants by innovative ("brand-name") pharmaceutical company plaintiffs asserting their Orange-Book-listed patents on drug products approved for marketing by the U.S. Food and Drug Administration, in exchange for delayed market entry of bioequivalent (generic) drugs coupled with the parties' withdrawal of their respective contentions in, and the termination of, the infringement action.

Last year, two closely watched and hotly debated cases at the interface between the patent and antitrust laws were decided by the U.S. Court of Appeals. The Eleventh Circuit in April 2012 in what later became known as FTC v. Actavis, Inc. ("the Androgel case") held that payments made by brand-name patent holders to potential generic entrants in exchange for the latters' delayed market entry in settlement of Paragraph IV litigations were, in effect, per se legal if such settlements fell within the bounds of the so-called "scope of the patent test". Three months later, the Third Circuit in Louisiana Wholesale Drug Co., Inc. v. Merck & Co. et al. ("the K-Dur case II"), in stark conflict with the Eleventh Circuit, held that such settlements are, in effect, presumptively illegal.

For further details about this event, please visit:

http://www.knowledgecongress.org/event_2013_US_Supreme_Court.html

Speakers/Faculty Panel

Charles Miller, Senior Counsel, Intellectual Property Law Practice Group, Sills Cummis & Gross P.C.

Mark Woodward, Attorney, Federal Trade Commission

James Langenfeld, Ph.D., Managing Director, Navigant Economics

Professor C. Scott Hemphill, Professor of Law, Columbia University Law School

About The Knowledge Group, LLC/The Knowledge Congress Live Webcast Series

The Knowledge Congress is a series of live webcasts produced by The Knowledge Group, LLC, which examine trends, regulatory, and technology changes across a variety of industries.

Contact information:

The Knowledge Group, LLC/The Knowledge Congress Live Webcast Series

http://www.knowledgecongress.org

info@knowledgecongress.org
End
Source:The Knowledge Group, LLC
Email:***@knowledgecongress.org Email Verified
Tags:Actavis, Ftc, Patent Litigation
Industry:Banking
Location:New York City - New York - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
The Knowledge Group News
Trending
Most Viewed
Daily News



Like PRLog?
9K2K1K
Click to Share